TPST-1120
TPST-1120-301
Phase 3 small_molecule active
Quick answer
TPST-1120 for Hepatocellular Carcinoma (HCC) is a Phase 3 program (small_molecule) at Tempest Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Tempest Therapeutics
- Indication
- Hepatocellular Carcinoma (HCC)
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active